公开(公告)号：EP1572930A2

公开(公告)日：2005-09-14

申请号：EP03737682.9

申请日：2003-02-07

申请人： Delta Biotechnology Limited ,  Dyax Corp.

发明人： HAUSER, Hans-Peter ,  WEIMER, Thomas ,  ROMBERG, Val ,  KEE, Scott, M. ,  SLEEP, Darrell ,  LADNER, Robert, Charles ,  LEY, Arthur, C.

IPC分类号： C12N1/00

CPC分类号： A61K47/48315 ,  A01K2217/05 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/00 ,  A61K38/39 ,  A61K39/00 ,  A61K39/0005 ,  A61K47/643 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/005 ,  C07K14/47 ,  C07K14/765 ,  C07K14/78 ,  C07K14/8114 ,  C07K2319/00 ,  C07K2319/31 ,  C12N15/62 ,  C12N2740/16122 ,  C12Y301/26003

摘要： The invention relates to albumin fusion proteins comprising an albumin fusion partner and a protease inhibitor fusion partner which may be a Kunitz domain protease inhibitor capable of inhibiting a serine protease, including neutrophil elastase, kallikrein, and plasm The fusion proteins exhibit extended shelf life and/or extended therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits comprising the albumin fusion proteins, a well as nucleic acid molecules encoding the albumin fusion proteins, vectors comprising these nucleic acids, host cells transformed w these nucleic acids and vectors, and methods of making the encoded proteins using the nucleic acids, vectors and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin, and to compositions an methods for treating cystic fibrosis and cancer.